Crescent Biopharma (CBIO) Assets (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Assets of $182.8 million for Q2 2026, up 16.09% year-over-year from $157.4 million in Q2 2025, and down 8.22% quarter-over-quarter from $199.1 million in Q1 2026.
Crescent Biopharma (CBIO) Assets (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Assets for 14 consecutive years, with $182.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets rose 16.09% year-over-year to $182.8 million; the TTM figure through Jun 2026 stood at $182.8 million (up 16.09% YoY), while the FY2025 annual figure was $240.3 million, up 574.66% from the prior year.
- Assets fell to $182.8 million in Q2 2026 per CBIO's latest filing, from $199.1 million in the prior quarter.
- Across five years, Assets topped out at $240.3 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
- Historically, Assets has averaged $84.3 million across 5 years, with a median of $58.9 million in 2022.
- Annual changes were most pronounced in 2025 — Assets sank 82.48% — and 2026, when it soared 3223.16%.
- Crescent Biopharma's Assets stood at $51.8 million in 2022, then dropped by 12.53% to $45.3 million in 2023, then retreated by 21.4% to $35.6 million in 2024, then soared by 574.66% to $240.3 million in 2025, then declined by 23.94% to $182.8 million in 2026.
- Business Quant data shows CBIO's Assets at $182.8 million in Q2 2026, $199.1 million in Q1 2026, and $240.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 182.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 182.76 Mn |
| Mar 31, 2026 | 199.13 Mn |
| Dec 31, 2025 | 240.29 Mn |
| Sep 30, 2025 | 138.27 Mn |
| Jun 30, 2025 | 157.43 Mn |
| Mar 31, 2025 | 5.99 Mn |
| Dec 31, 2024 | 35.62 Mn |
| Sep 30, 2024 | 15.70 Mn |
| Jun 30, 2024 | 24.42 Mn |
| Mar 31, 2024 | 34.20 Mn |
| Dec 31, 2023 | 45.32 Mn |
| Sep 30, 2023 | 53.20 Mn |
| Jun 30, 2023 | 61.82 Mn |
| Mar 31, 2023 | 68.92 Mn |
| Dec 31, 2022 | 51.81 Mn |
| Sep 30, 2022 | 55.96 Mn |
| Jun 30, 2022 | 65.04 Mn |
| Mar 31, 2022 | 81.46 Mn |
| Dec 31, 2021 | 94.35 Mn |
| Sep 30, 2021 | 107.94 Mn |